

n q ygt " vjpc ð ð vjpc v/ "ghfop" {pgiofgt5/ g rfg 3n4{ + " Ocý E gppovk Y ð y g 500c'p

**Conclusions:** Consciousness level and sex were significant prognostic factors for survival. The elderly patients were more likely to be end-of-life.



---

**\*Corresponding author:** Shuji Hiramoto, Department of Clinical Oncology and Palliative Medicine, Mitsubishi Kyoto Hospital, Kyoto, Japan, Tel: 81-775-270-989; [shuji.hiramoto@mkh.mitsubishi.com](mailto:shuji.hiramoto@mkh.mitsubishi.com)

**Received** May 22, 2021; **Accepted** July 05, 2021; **Published** July 12, 2021

**Citation:** Hiramoto S, Hori T, Kikuchi A, Yoshioka A, Tamaki T (2021) Prognostic Factors and Clinical Characteristics in Elderly Patients with Advanced Cancer at the End-of-Life.

e h e ede a e a 140 (27.5%) a d -e de  
 370 (72.5%). 510 a e d e d a e d  
 e d, 171 a e e e ed e a e . e e , 31  
 a e e e e ded a a e a e a ad a a -  
 a e e a e d e a (F e 1).

e a e d a a de a e de  
 a e a d a e d a e a e e d - e p . e e da  
 e d a a a e e e a h e e e de a e d - e  
 a e a da - a e e a e a d e a e.

**Procedure**

Ve e ed h a e e da a e a d e , a a e e ,  
 a a e , h e h d e , h e e a a e ,  
 E a e e a e e e a e a (E + p ),  
 e e e , e e a e e , e e a h e e ,  
 e e d ( a ) e e , e e - e a e e ( R p ) e e  
 a d e a e e e e e d e e a . e e e a  
 a e d e e a (300), a (200), e a (100),  
 (30), e a (20), d e (10), de (3), (2),  
 e e e (1) a d a (0) a da e e a a  
 a e [16]. Ve de ed 10-300 a e a d 0-3 a  
 a . I e a a , e ed h e a a a e  
 a d a a e a a .

Re a d e d - e , e e ed e a e e a  
 e e da e e a e a , de , a e a d ,  
 a e a d d e a h a a e a e a a e  
 e a a e a da a a e . e a da ed  
 0

Citation:

Reason for why discontinuation of anti-cancer treatment				
	Chemo line>1	Performance status in last administration>1	Number of cytotoxic agent in last administration>1	By image diagnosis (ID)
Elderly (N=45)	20 (44.4 )	19 (42.2 )	6 (13.3 )	11
Non-elderly (N=263)	172 (65.4 )	95 (36.1 )	81 (30.8 )	75
P-value	0.007	0.203	0.016	0.574
Reason for why discontinuation of anti-cancer treatment				
	By clinical diagnosis(CD)	By adverse event(AD)	By patients' demand(PD)	By completion
Elderly (N=45)	12	9	4	0
Non-elderly (N=263)	77	36	8	9
P-value	0.721	0.268	0.061	0.208
Reason for why discontinuation of anti-cancer treatment				
	By acute death	By decline of performance status(PS)	By others	Unknown
Elderly (N=45)	2	7	4	2
Non-elderly (N=263)	14	38	0	0
P-value	0.806	0.846	0.405	0.557

Table 3: Relationship between details of anti-cancer treatment and their age (N=308).

Prognostic factor		Univariate analysis			Multivariate analysis		
		HR	95%Confidential interval	P-value	HR	95%Confidential interval	P-value
Sex	Male/Female	1.252	0.892-1.759	0.194	1.531	1.017-2.323	0.041
Primary site	EG,BP/Others	0.953	0.675-1.334	0.779	1.105	0.702-1.742	0.667
Clinical Stage	Recurrence/Stage II-IV	1.12	0.758-1.620	0.561	1.017	0.638-1.595	0.941
Number of comorbidity	2/0-1	1.138	0.719-1.731	0.567	1.403	0.819-2.318	0.211
Number of meta	2/0-1	1.291	0.864-1.881	0.206	1.159	0.695-1.879	0.563
ECOG-PS	2-4/0-1	1.364	0.515-5.540	0.577	1.58	0.564-6.599	0.421
Consciousness level	10-300/0-3	1.12	0.758-1.620	0.561	1.714	1.006-2.827	0.048
Ca	>10.3/ 10.3	1.1	0.756-1.589	0.615	0.979	0.629-1.533	0.925
ALB	<3.5/ 3.5	1.601	0.886-3.209	0.125	1.172	0.566-2.645	0.681
Na	<135/ 135	1.317	0.919-1.869	0.132	1.348	0.851-2.092	0.199
CRP	>1.0/ 1.0	1.848	1.137-3.181	0.012	1.595	0.908-2.971	0.107
Chemotherapy	+/-	0.885	0.615-1.258	0.501	0.911	0.594-1.374	0.66

Table 4: Prognostic factors analysis for survival time of the elderly patients (over 80 years old) in end-of-life settings (N=140).

Abbreviation: EG: Esophageal-Gastric Cancer; BP: Biliary-Pancreatic Cancer; HR: Hazard Ratio

Prognostic Factor		Univariate Analysis			Multivariate Analysis		
		HR	95% Confidential interval	P-value	HR	95% Confidential interval	P-Value
Sex	Male/Female	1.236	1.001-1.531	0.049	1.191	0.922-1.548	0.183
Primary site	EG,BP/ Others	1.042	0.846-1.281	0.696	1.112	0.859-1.438	0.417
Clinical Stage	Recurrence/ Stage II-IV	0.921	0.741-1.141	0.456	1.059	0.805-1.383	0.678
Number of comorbidity	2/0-1	1.076	0.784-1.444	0.643	1.097	0.742-1.582	0.635
Number of meta	2/0-1	0.835	0.675-1.030	0.092	0.822	0.527-1.070	0.146
ECOG-PS	2-4/0-1	2.862	1.439-6.799	0.002	1.46	0.592-4.853	0.445
Consciousness level	10-300/0-3	2.984	2.201-3.971	<0.001	2.754	1.909-3.880	<0.001
Ca	>10.3/ 10.3	1.549	1.211-1.975	<0.001	1.702	1.306-2.215	<0.001
ALB	<3.5/ 3.5	1.19	0.843-1.737	0.334	1.027	0.647-1.689	0.914
Na	<135/ 135	1.129	0.918-1.386	0.249	0.991	0.754-1.296	0.948
CRP	>1.0/ 1.0	1.443	1.055-2.026	0.021	1.4a.822 T7P.G503 -1.82306-2.2074		

e a e e a e a e e de a e a 27.9%, a  
a e a -e de a e (37.6%). e e a e e  
a e de e da a e e de a e a 12.9%,  
a a e a -e de a e (28.9%). e  
ea d d e e de a e a 23.3 /da , a  
a e a a -e de a e (43.8 /da )  
(Table 6).

19. Nozoe T, Ninomiya M, Maeda T, Matsukuma A, Nakashima H, et al. (2010) Prognostic nutritional index: a tool to predict the biological aggressiveness of gastric carcinoma. *Surg Today* 40:440-443
20. Hiramoto S, Kato K, Shoji H, Okita N, Takashima A, et al. (2018) A retrospective analysis of 5-fluorouracil plus cisplatin as first line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma. *Int J Clin Oncol* 23:466-472.
21. Japanese guidelines for diagnosis and treatment of the lung cancer (2018).